University of Edinburgh
Translational insights into ApoE4-related vascular dysfunction: from preclinical models to clinical exploration
Abstract
dc:description.abstractApolipoprotein E (APOE) is a multifunctional lipid transporter involved in lipoprotein metabolism and cholesterol regulation. The E4 variant (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) and has been linked to other conditions, including vascular dementia, atherosclerosis, and cardiovascular disease. As of 2019, up to 60% of AD patients are estimated to carry at least one APOE4 allele, ultimately affecting over 25 million people worldwide. While APOE4-related mechanisms such as amyloid-β accumulation and neuroinflammation have been extensively studied, its role in vascular dysfunction remains less well understood. This thesis investigates the contribution of APOE4 to cerebrovascular pathology using systematic, quantitative, and translational approaches spanning both preclinical models and clinical data. The overarching aim of this thesis was to investigate the role of APOE4 in blood-brain barrier dysfunction, to characterise genotype-dependent differences and assess their potential contribution to early pathophysiological changes. First, a systematic review and meta-analysis (PROSPERO ID: CRD420251010665), conducted in accordance with PRISMA 2020 guidelines, evaluated the impact of APOE4 on vascular alterations in humanised transgenic APOE mouse models, with a focus on vascular morphology and cerebral blood flow (CBF). Evidence supported genotype-dependent differences in vascular morphology, BBB permeability, and cerebral blood flow. Narrative synthesis identified three key mechanistic pathways linking APOE4 to vascular dysfunction. Next, longitudinal experimental studies were performed in APOE3 and APOE4 knock-in mice, incorporating behavioural testing, immunohistochemistry, microvessel proteomics, and magnetic resonance imaging (MRI). Mice were assessed at timepoints corresponding to human developmental stages: early adulthood (2-4 mo.), mature adulthood (7-9 mo.), middle age (12-14 mo.), and late life (17-19 mo.). Analyses revealed age- and genotype-specific vascular alterations. Proteomic and histological analyses implicated dysregulation of mitochondrial function, extracellular matrix remodelling and altered expression of key markers such as VEGFR2. Finally, in a prospective human stroke cohort, associations between APOE genotype and BBB integrity were evaluated using dynamic contrast-enhanced MRI and infarct characterisation. APOE4 carriers demonstrated posterior bias in infarct distribution and evidence of BBB disruption, echoing findings in the preclinical models. Collectively, the findings of this thesis support APOE4 as a driver of cerebrovascular dysfunction through mechanisms of vascular destabilisation. These alterations may underlie early cognitive changes and contribute to the vascular basis of APOE4 associated disease risk. The translational insights presented here provide groundwork for research which may inform future strategies aimed at improving diagnostic and therapeutic outcomes for APOE4 carriers.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Laing, Krystal Kreshé
- Advisors dc:contributor.advisor
-
- Wardlaw, Joanna
- Montagne, Axel
- Price, David
Subjects
dc:subject × 5Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.7488/era/7732